Vanderbilt-Ingram Cancer Center

The VICC.ORG Investigator Directory

Dan M. Roden, M.D.

Professor of Medicine and Pharmacology
William Stokes Professor of Experimental Therapeutics
VICC Member
Researcher

Contact Information:

Vanderbilt University Medical Center
536 Robinson Research Building
Nashville, TN 37232-6602
615-322-0067

Research Specialty:

Mechanisms and treatment of cardiac arrhythmias

Research Description:

Abnormalities of cardiac rhythm are a common and serious public health problem. However, the therapies used to treat arrhythmias are often ineffective, and can sometimes even exacerbate arrhythmias. Research in this laboratory is directed at elucidating mechanisms underlying abnormalities of cardiac rhythm and mechanisms underlying variable responses to antiarrhythmic drug treatments. Since antiarrhythmic drugs affect the function of cardiac ion channels, it is one working hypothesis in the laboratory that variable responses to drug therapy may reflect variable function or expression of genes encoding ion channels or proteins involved in drug disposition. Thus, a major focus of work in the laboratory is elucidation of factor(s) that determine ion channel gene expression in cardiac tissue. Approaches include identification of new genes, identification of DNA polymorphisms and characterization of their functional effects on disease and drug responses, and modulation of expression in cultured heart cells (e.g. by antisense) and gene knockout in mice.

Clinical Interest:

We are interested in variability in arrhythmia presentations and their response to therapies, particularly as a function of genetic background.

Publications:

• Delaney, JT, Muhammad, R, Blair, MA, Kor, K, Fish, FA, Roden, DM, Darbar, D A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace, 2012.
• Parvez, B, Chopra, N, Rowan, S, Vaglio, JC, Muhammad, R, Roden, DM, Darbar, D A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol, 59(1), 49-56, 2012.
• Yang, T, Atack, TC, Stroud, DM, Zhang, W, Hall, L, Roden, DM Blocking scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res, 111(3), 322-32, 2012.
• Delaney, JT, Jeff, JM, Brown, NJ, Pretorius, M, Okafor, HE, Darbar, D, Roden, DM, Crawford, DC Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PLoS One, 7(2), e32338, 2012.
• Ritchie, MD, Rowan, S, Kucera, G, Stubblefield, T, Blair, M, Carter, S, Roden, DM, Darbar, D Chromosome 4q25 Variants Are Genetic Modifiers of Rare Ion Channel Mutations Associated With Familial Atrial Fibrillation. J Am Coll Cardiol, 2012.
• Roden, DM, Xu, H, Denny, JC, Wilke, RA Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges. Clin Pharmacol Ther, 2012.
• Wells, QS, Delaney, JT, Roden, DM Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol, 27(3), 253-61, 2012.
• Lowe, JS, Stroud, DM, Yang, T, Hall, L, Atack, TC, Roden, DM Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res, 2012.
• Ramirez, AH, Shaffer, CM, Delaney, JT, Sexton, DP, Levy, SE, Rieder, MJ, Nickerson, DA, George, AL, Roden, DM Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J, 2012.
• Pulley, JM, Denny, JC, Peterson, JF, Bernard, GR, Vnencak-Jones, CL, Ramirez, AH, Delaney, JT, Bowton, E, Brothers, K, Johnson, K, Crawford, DC, Schildcrout, J, Masys, DR, Dilks, HH, Wilke, RA, Clayton, EW, Shultz, E, Laposata, M, McPherson, J, Jirjis, JN, Roden, DM Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther, 92(1), 87-95, 2012.
• Schildcrout, JS, Denny, JC, Bowton, E, Gregg, W, Pulley, JM, Basford, MA, Cowan, JD, Xu, H, Ramirez, AH, Crawford, DC, Ritchie, MD, Peterson, JF, Masys, DR, Wilke, RA, Roden, DM Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther, 92(2), 235-42, 2012.
• Delaney, JT, Ramirez, AH, Bowton, E, Pulley, JM, Basford, MA, Schildcrout, JS, Shi, Y, Zink, R, Oetjens, M, Xu, H, Cleator, JH, Jahangir, E, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther, 91(2), 257-63, 2012.
• Ramirez, AH, Shi, Y, Schildcrout, JS, Delaney, JT, Xu, H, Oetjens, MT, Zuvich, RL, Basford, MA, Bowton, E, Jiang, M, Speltz, P, Zink, R, Cowan, J, Pulley, JM, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics, 13(4), 407-18, 2012.
• Monahan, K, Brewster, J, Wang, L, Parvez, B, Goyal, S, Roden, DM, Darbar, D Relation of the Severity of Obstructive Sleep Apnea in Response to Anti-Arrhythmic Drugs in Patients With Atrial Fibrillation or Atrial Flutter. Am J Cardiol, 2012.
• Wilke, RA, Ramsey, LB, Johnson, SG, Maxwell, WD, McLeod, HL, Voora, D, Krauss, RM, Roden, DM, Feng, Q, Cooper-Dehoff, RM, Gong, L, Klein, TE, Wadelius, M, Niemi, M The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther, 92(1), 112-7, 2012.
• Barrett, TW, Storrow, AB, Jenkins, CA, Harrell, FE, Miller, KF, Moser, KM, Russ, S, Roden, DM, Darbar, D Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. J Cardiol, 58(2), 124-30, 2011.
• Roden, DM, Johnson, JA, Kimmel, SE, Krauss, RM, Medina, MW, Shuldiner, A, Wilke, RA Cardiovascular pharmacogenomics. Circ Res, 109(7), 807-20, 2011.
• Xu, H, Jiang, M, Oetjens, M, Bowton, EA, Ramirez, AH, Jeff, JM, Basford, MA, Pulley, JM, Cowan, JD, Wang, X, Ritchie, MD, Masys, DR, Roden, DM, Crawford, DC, Denny, JC Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc, 18(4), 387-91, 2011.
• Kannankeril, PJ, Norris, KJ, Carter, S, Roden, DM Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm, 8(10), 1530-4, 2011.
• Atack, TC, Stroud, DM, Watanabe, H, Yang, T, Hall, L, Hipkens, SB, Lowe, JS, Leake, B, Magnuson, MA, Yang, P, Roden, DM Informatic and functional approaches to identifying a regulatory region for the cardiac sodium channel. Circ Res, 109(1), 38-46, 2011.
• Turner, SD, Berg, RL, Linneman, JG, Peissig, PL, Crawford, DC, Denny, JC, Roden, DM, McCarty, CA, Ritchie, MD, Wilke, RA Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS One, 6(5), e19586, 2011.
• Liu, M, Jiang, M, Kawai, VK, Stein, CM, Roden, DM, Denny, JC, Xu, H Modeling drug exposure data in electronic medical records: an application to warfarin. AMIA Annu Symp Proc, 2011815-23, 2011.
• Roden, DM Personalized medicine and the genotype-phenotype dilemma. J Interv Card Electrophysiol, 31(1), 17-23, 2011.
• Roden, DM, Wilke, RA, Kroemer, HK, Stein, CM Pharmacogenomics: the genetics of variable drug responses. Circulation, 123(15), 1661-70, 2011.
• Watanabe, H, Yang, T, Stroud, DM, Lowe, JS, Harris, L, Atack, TC, Wang, DW, Hipkens, SB, Leake, B, Hall, L, Kupershmidt, S, Chopra, N, Magnuson, MA, Tanabe, N, Knollmann, BC, George, AL, Roden, DM Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation, 124(9), 1001-11, 2011.
• Denny, JC, Crawford, DC, Ritchie, MD, Bielinski, SJ, Basford, MA, Bradford, Y, Chai, HS, Bastarache, L, Zuvich, R, Peissig, P, Carrell, D, Ramirez, AH, Pathak, J, Wilke, RA, Rasmussen, L, Wang, X, Pacheco, JA, Kho, AN, Hayes, MG, Weston, N, Matsumoto, M, Kopp, PA, Newton, KM, Jarvik, GP, Li, R, Manolio, TA, Kullo, IJ, Chute, CG, Chisholm, RL, Larson, EB, McCarty, CA, Masys, DR, Roden, DM, de Andrade, M Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet, 89(4), 529-42, 2011.
• Abraham, RL, Yang, T, Blair, M, Roden, DM, Darbar, D Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J Mol Cell Cardiol, 48(1), 181-90, 2010.
• Roden, DM Brugada syndrome: lots of questions, some answers. Heart Rhythm, 7(1), 47-9, 2010.
• Ellinor, PT, Lunetta, KL, Glazer, NL, Pfeufer, A, Alonso, A, Chung, MK, Sinner, MF, de Bakker, PI, Mueller, M, Lubitz, SA, Fox, E, Darbar, D, Smith, NL, Smith, JD, Schnabel, RB, Soliman, EZ, Rice, KM, Van Wagoner, DR, Beckmann, BM, van Noord, C, Wang, K, Ehret, GB, Rotter, JI, Hazen, SL, Steinbeck, G, Smith, AV, Launer, LJ, Harris, TB, Makino, S, Nelis, M, Milan, DJ, Perz, S, Esko, T, Köttgen, A, Moebus, S, Newton-Cheh, C, Li, M, Möhlenkamp, S, Wang, TJ, Kao, WH, Vasan, RS, Nöthen, MM, MacRae, CA, Stricker, BH, Hofman, A, Uitterlinden, AG, Levy, D, Boerwinkle, E, Metspalu, A, Topol, EJ, Chakravarti, A, Gudnason, V, Psaty, BM, Roden, DM, Meitinger, T, Wichmann, HE, Witteman, JC, Barnard, J, Arking, DE, Benjamin, EJ, Heckbert, SR, Kääb, S Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet, 42(3), 240-4, 2010.
• Oshiro, C, Thorn, CF, Roden, DM, Klein, TE, Altman, RB KCNH2 pharmacogenomics summary. Pharmacogenet Genomics, 2010.
• Denny, JC, Ritchie, MD, Basford, MA, Pulley, JM, Bastarache, L, Brown-Gentry, K, Wang, D, Masys, DR, Roden, DM, Crawford, DC PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics, 26(9), 1205-10, 2010.
• Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , , , , , Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol, 55(9), 934-47, 2010.
• Drew, BJ, Ackerman, MJ, Funk, M, Gibler, WB, Kligfield, P, Menon, V, Philippides, GJ, Roden, DM, Zareba, W, , Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation, 121(8), 1047-60, 2010.
• Pulley, J, Clayton, E, Bernard, GR, Roden, DM, Masys, DR Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci, 3(1), 42-8, 2010.
• Ritchie, MD, Denny, JC, Crawford, DC, Ramirez, AH, Weiner, JB, Pulley, JM, Basford, MA, Brown-Gentry, K, Balser, JR, Masys, DR, Haines, JL, Roden, DM Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet, 86(4), 560-72, 2010.
• Chopra, SS, Stroud, DM, Watanabe, H, Bennett, JS, Burns, CG, Wells, KS, Yang, T, Zhong, TP, Roden, DM Voltage-gated sodium channels are required for heart development in zebrafish. Circ Res, 106(8), 1342-50, 2010.
• Limdi, NA, Wadelius, M, Cavallari, L, Eriksson, N, Crawford, DC, Lee, MT, Chen, CH, Motsinger-Reif, A, Sagreiya, H, Liu, N, Wu, AH, Gage, BF, Jorgensen, A, Pirmohamed, M, Shin, JG, Suarez-Kurtz, G, Kimmel, SE, Johnson, JA, Klein, TE, Wagner, MJ, , Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 115(18), 3827-34, 2010.
• Watanabe, H, Kaiser, DW, Makino, S, MacRae, CA, Ellinor, PT, Wasserman, BS, Kannankeril, PJ, Donahue, BS, Roden, DM, Darbar, D ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm, 6(9), 1327-32, 2009.
• Roden, DM, Kannankeri, PJ, Darbar, D Arrhythmia pharmacogenomics: methodological considerations. Curr Pharm Des, 15(32), 3734-41, 2009.
• Yang, T, Chung, SK, Zhang, W, Mullins, JG, McCulley, CH, Crawford, J, MacCormick, J, Eddy, CA, Shelling, AN, French, JK, Yang, P, Skinner, JR, Roden, DM, Rees, MI Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol, 2(4), 417-26, 2009.
• Raj, SR, Stein, CM, Saavedra, PJ, Roden, DM Cardiovascular effects of noncardiovascular drugs. Circulation, 120(12), 1123-32, 2009.
• Watanabe, H, Watanabe, T, Sasaki, S, Nagai, K, Roden, DM, Aizawa, Y Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J, 158(4), 629-36, 2009.
• Milan, DJ, Kim, AM, Winterfield, JR, Jones, IL, Pfeufer, A, Sanna, S, Arking, DE, Amsterdam, AH, Sabeh, KM, Mably, JD, Rosenbaum, DS, Peterson, RT, Chakravarti, A, Kääb, S, Roden, DM, MacRae, CA Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation, 120(7), 553-9, 2009.
• Postema, PG, Wolpert, C, Amin, AS, Probst, V, Borggrefe, M, Roden, DM, Priori, SG, Tan, HL, Hiraoka, M, Brugada, J, Wilde, AA Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 6(9), 1335-41, 2009.
• Watanabe, H, Chopra, N, Laver, D, Hwang, HS, Davies, SS, Roach, DE, Duff, HJ, Roden, DM, Wilde, AA, Knollmann, BC Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med, 15(4), 380-3, 2009.
• Bush, WS, Crawford, DC, Alexander, C, George, AL, Roden, DM, Ritchie, MD Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. Pharmacogenomics, 10(6), 1043-53, 2009.
• McBride, BF, Yang, T, Roden, DM Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J, 9(3), 194-201, 2009.
• Kääb, S, Darbar, D, van Noord, C, Dupuis, J, Pfeufer, A, Newton-Cheh, C, Schnabel, R, Makino, S, Sinner, MF, Kannankeril, PJ, Beckmann, BM, Choudry, S, Donahue, BS, Heeringa, J, Perz, S, Lunetta, KL, Larson, MG, Levy, D, MacRae, CA, Ruskin, JN, Wacker, A, Schömig, A, Wichmann, HE, Steinbeck, G, Meitinger, T, Uitterlinden, AG, Witteman, JC, Roden, DM, Benjamin, EJ, Ellinor, PT Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J, 30(7), 813-9, 2009.
• Watanabe, H, Darbar, D, Kaiser, DW, Jiramongkolchai, K, Chopra, S, Donahue, BS, Kannankeril, PJ, Roden, DM Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ Arrhythm Electrophysiol, 2(3), 268-75, 2009.
• Yang, T, Kanki, H, Zhang, W, Roden, DM Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I(Ks) block by protein kinase A-mediated I(Ks) phosphorylation. Br J Pharmacol, 157(6), 952-61, 2009.
• Li, C, Schwarz, UI, Ritchie, MD, Roden, DM, Stein, CM, Kurnik, D Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 113(17), 3925-30, 2009.
• Body, SC, Collard, CD, Shernan, SK, Fox, AA, Liu, KY, Ritchie, MD, Perry, TE, Muehlschlegel, JD, Aranki, S, Donahue, BS, Pretorius, M, Estrada, JC, Ellinor, PT, Newton-Cheh, C, Seidman, CE, Seidman, JG, Herman, DS, Lichtner, P, Meitinger, T, Pfeufer, A, Kääb, S, Brown, NJ, Roden, DM, Darbar, D Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet, 2(5), 499-506, 2009.
• Knollmann, BC, Roden, DM A genetic framework for improving arrhythmia therapy. Nature, 451(7181), 929-36, 2008.
• Rhodes, TE, Abraham, RL, Welch, RC, Vanoye, CG, Crotti, L, Arnestad, M, Insolia, R, Pedrazzini, M, Ferrandi, C, Vege, A, Rognum, T, Roden, DM, Schwartz, PJ, George, AL Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol, 44(3), 571-81, 2008.
• Darbar, D, Kannankeril, PJ, Donahue, BS, Kucera, G, Stubblefield, T, Haines, JL, George, AL, Roden, DM Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation, 117(15), 1927-35, 2008.
• Roden, DM Cellular basis of drug-induced torsades de pointes. Br J Pharmacol, 154(7), 1502-7, 2008.
• Roden, DM Clinical practice. Long-QT syndrome. N Engl J Med, 358(2), 169-76, 2008.
• Roden, D, Pulley, J, Basford, M, Bernard, G, Clayton, E, Balser, J, Masys, D Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine. Clin Pharmacol Ther, 2008.
• Schwarz, UI, Ritchie, MD, Bradford, Y, Li, C, Dudek, SM, Frye-Anderson, A, Kim, RB, Roden, DM, Stein, CM Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 358(10), 999-1008, 2008.
• Roden, DM Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm, 5(8), 1213-5, 2008.
• Darbar, D, Kimbrough, J, Jawaid, A, McCray, R, Ritchie, MD, Roden, DM Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol, 51(8), 836-42, 2008.
• Yang, P, Koopmann, TT, Pfeufer, A, Jalilzadeh, S, Schulze-Bahr, E, Kääb, S, Wilde, AA, Roden, DM, Bezzina, CR Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet, 16(3), 350-7, 2008.
• Darbar, D, Hardy, A, Haines, JL, Roden, DM Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J Am Coll Cardiol, 51(11), 1083-9, 2008.
• Kannankeril, PJ, Harris, PA, Norris, KJ, Warsy, I, Smith, PD, Roden, DM Rate-Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise. J Cardiovasc Electrophysiol, 2008.
• Watanabe, H, Koopmann, TT, Le Scouarnec, S, Yang, T, Ingram, CR, Schott, JJ, Demolombe, S, Probst, V, Anselme, F, Escande, D, Wiesfeld, AC, Pfeufer, A, Kääb, S, Wichmann, HE, Hasdemir, C, Aizawa, Y, Wilde, AA, Roden, DM, Bezzina, CR Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest, 118(6), 2260-8, 2008.
• Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Schott J-J, Norris K, Kim RB, Escande D, Roden DM: "Dysfunctional ankyrin-B variants with a spectrum of altered function are present in diverse human populations.." Circulation , 115432-441, 2007.
• Monahan, K, Clair, W, Roden, DM A memorable experience. Europace, 2007.
• Darbar, D, Hardin, B, Harris, P, Roden, DM A rate-independent method of assessing QT-RR slope following conversion of atrial fibrillation. J Cardiovasc Electrophysiol, 18(6), 636-41, 2007.
• Fitch, RW, Gregory, A, Darbar, D, Roden, DM A shock in time. Clin J Sport Med, 17(6), 497-9, 2007.
• Smith, AH, Norris, KJ, Roden, DM, Kannankeril, PJ Autonomic tone attenuates drug-induced QT prolongation. J Cardiovasc Electrophysiol, 18(9), 960-4, 2007.
• Kannankeril, PJ, Roden, DM Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol, 22(1), 39-43, 2007.
• Chopra, SS, Watanabe, H, Zhong, TP, Roden, DM Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates. BMC Evol Biol, 7113, 2007.
• Roden, DM, Kannankeril, P, Darbar, D On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace, 9 Suppl 4iv1-3, 2007.
• Pretorius, M, Donahue, BS, Yu, C, Greelish, JP, Roden, DM, Brown, NJ Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation, 116(11 Suppl), I1-7, 2007.
• Darbar, D, Motsinger, AA, Ritchie, MD, Gainer, JV, Roden, DM Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm, 4(6), 743-9, 2007.
• Kannankeril, PJ, Roden, DM When should QT be measured? Summer solstice or Christmas Eve. Heart Rhythm, 4(3), 282-3, 2007.
• Kannankeril, PJ, Bhuiyan, ZA, Darbar, D, Mannens, MM, Wilde, AA, Roden, DM Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. Heart Rhythm, 3(8), 939-44, 2006.
• Knollmann, BC, Chopra, N, Hlaing, T, Akin, B, Yang, T, Ettensohn, K, Knollmann, BE, Horton, KD, Weissman, NJ, Holinstat, I, Zhang, W, Roden, DM, Jones, LR, Franzini-Armstrong, C, Pfeifer, K Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest, 116(9), 2510-20, 2006.
• Bezzina CR, Shimizu W, Yang P, Koopmann T, Tanck MWT, Miyamoto Y, Kamakura S, Roden DM, Wilde AAM "Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction.." Circulation , 113338-344, 2006.
• Darbar, D, Roden, DM Future of antiarrhythmic drugs. Curr Opin Cardiol, 21(4), 361-7, 2006.
• Roden, DM Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med, 259(1), 59-69, 2006.
• Kannankeril, PJ, Mitchell, BM, Goonasekera, SA, Chelu, MG, Zhang, W, Sood, S, Kearney, DL, Danila, CI, De Biasi, M, Wehrens, XH, Pautler, RG, Roden, DM, Taffet, GE, Dirksen, RT, Anderson, ME, Hamilton, SL Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A, 103(32), 12179-84, 2006.
• Darbar, D, Roden, DM Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother, 7(12), 1583-90, 2006.
• Roden, DM, Altman, RB, Benowitz, NL, Flockhart, DA, Giacomini, KM, Johnson, JA, Krauss, RM, McLeod, HL, Ratain, MJ, Relling, MV, Ring, HZ, Shuldiner, AR, Weinshilboum, RM, Weiss, ST, , Pharmacogenomics: challenges and opportunities. Ann Intern Med, 145(10), 749-57, 2006.
• Roden, DM, Anderson, ME Proarrhythmia. Handb Exp Pharmacol, (171), 73-97, 2006.
• Liu, K, Hipkens, S, Yang, T, Abraham, R, Zhang, W, Chopra, N, Knollmann, B, Magnuson, MA, Roden, DM Recombinase-mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels. Genesis, 44(11), 556-64, 2006.
• Motsinger, AA, Donahue, BS, Brown, NJ, Roden, DM, Ritchie, MD Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pac Symp Biocomput, 584-95, 2006.
• Page RL, Roden DM "Drug therapy for atrial fibrillation.." Nature Drug Discovery, 4899-910, 2005.
• Roden DM "Principles of Clinical Pharmacology.." In Sixteenth Edition of Harrison’s Principles of Internal Medicine, 13-25, 2005.
• Roden DM: "An under-recognized challenge in evaluating post-marketing drug safety.." Circulation, 111246-8, 2005.
• Roden, DM An underrecognized challenge in evaluating postmarketing drug safety. Circulation, 111(3), 246-8, 2005.
• Temple, J, Frias, P, Rottman, J, Yang, T, Wu, Y, Verheijck, EE, Zhang, W, Siprachanh, C, Kanki, H, Atkinson, JB, King, P, Anderson, ME, Kupershmidt, S, Roden, DM Atrial fibrillation in KCNE1-null mice. Circ Res, 97(1), 62-9, 2005.
• Khoo, MS, Kannankeril, PJ, Li, J, Zhang, R, Kupershmidt, S, Zhang, W, Atkinson, JB, Colbran, RJ, Roden, DM, Anderson, ME Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. Heart Rhythm, 2(6), 634-40, 2005.
• Roden DM, Yang T "Editorial - Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve.." Circulation , 1121376-1378, 2005.
• Kannankeril, PJ, Roden, DM, Norris, KJ, Whalen, SP, George, AL, Murray, KT Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm, 2(2), 134-40, 2005.
• Roden, DM, Viswanathan, PC Genetics of acquired long QT syndrome. J Clin Invest, 115(8), 2025-32, 2005.
• Roden DM, Viswanathan PC "Genetics of acquired long QT syndrome.." J Clin Invest , 1152025-2032, 2005.
• Drolet, B, Simard, C, Mizoue, L, Roden, DM Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest, 115(8), 2209-13, 2005.
• Darbar, D, Roden, DM, Ali, MF, Yang, T, Wathen, MS Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. Circulation, 111(11), e161, 2005.
• Crotti, L, Lundquist, AL, Insolia, R, Pedrazzini, M, Ferrandi, C, De Ferrari, GM, Vicentini, A, Yang, P, Roden, DM, George, AL, Schwartz, PJ KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. Circulation, 2005.
• Liu, K, Yang, T, Viswanathan, PC, Roden, DM New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation, 112(21), 3239-46, 2005.
• Todd, SJ, Campbell, MJ, Roden, DM, Kannankeril, PJ Novel Brugada SCN5A mutation causing sudden death in children. Heart Rhythm, 2(5), 540-3, 2005.
• Simard, C, Drolet, B, Yang, P, Kim, RB, Roden, DM Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther, 77(3), 138-44, 2005.
• Roden, DM Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res, 67(3), 419-25, 2005.
• Darbar, D, Roden, DM Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. Heart Rhythm, 2(5), 544-9, 2005.
• Roden, DM, Temple, R The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Circulation, 111(13), 1697-702, 2005.
• Roden DM and Temple R "The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.." Circulation , 1111697-1702, 2005.
• Bezzina, CR, Wilde, AA, Roden, DM The molecular genetics of arrhythmias. Cardiovasc Res, 67(3), 343-6, 2005.
• Darbar, D, Yang, T, Churchwell, K, Wilde, AA, Roden, DM Unmasking of brugada syndrome by lithium. Circulation, 112(11), 1527-31, 2005.
• Kanki, H, Kupershmidt, S, Yang, T, Wells, S, Roden, DM A structural requirement for processing the cardiac K+ channel KCNQ1. J Biol Chem, 279(32), 33976-83, 2004.
• Yang, Ping, Kupershmidt, Sabina, Roden, Dan M Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. Cardiovasc Res, 61(1), 56-65, 2004.
• Roden, Dan M Drug-induced prolongation of the QT interval. N Engl J Med, 350(10), 1013-22, 2004.
• Fenichel, RR, Malik, M, Antzelevitch, C, Sanguinetti, M, Roden, DM, Priori, SG, Ruskin, JN, Lipicky, RJ, Cantilena, LR, , Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol, 15(4), 475-95, 2004.
• Roden, DM Human genomics and its impact on arrhythmias. Trends Cardiovasc Med, 14(3), 112-6, 2004.
• Petersen, CI, McFarland, TR, Stepanovic, SZ, Yang, P, Reiner, DJ, Hayashi, K, George, AL, Roden, DM, Thomas, JH, Balser, JR In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci U S A, 101(32), 11773-8, 2004.
• Jay, PY, Harris, BS, Maguire, CT, Buerger, A, Wakimoto, H, Tanaka, M, Kupershmidt, S, Roden, DM, Schultheiss, TM, O'Brien, TX, Gourdie, RG, Berul, CI, Izumo, S Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest, 113(8), 1130-7, 2004.
• Kannankeril, PRINCE J., Roden, DAN M., Fish, FRANK A. Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen''s Syndrome. J Cardiovasc Electrophysiol, 15(1), 119, 2004.
• Drolet, Benoit, Simard, Chantale, Roden, Dan M Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109(1), 26-9, 2004.
• Roden, Dan M A surprising new arrhythmia mechanism in heart failure. Circ Res, 93(7), 589-91, 2003.
• Roden, Dan M Antiarrhythmic drugs: past, present and future. J Cardiovasc Electrophysiol, 14(12), 1389-96, 2003.
• Roden, Dan M Antiarrhythmic drugs: past, present, and future. Pacing Clin Electrophysiol, 26(12), 2340-9, 2003.
• Laohakunakorn, P, Benson, DW, Yang, P, Yang, T, Roden, DM, Kugler, JD Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol, 92(8), 991-5, 2003.
• Roden, Dan M Cardiovascular pharmacogenomics. Circulation, 108(25), 3071-4, 2003.
• Johnson, Walter H, Yang, Ping, Yang, Tao, Lau, Yung R, Mostella, Barbara A, Wolff, Daynna J, Roden, Dan M, Benson, D Woodrow Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome. Pediatr Res, 53(5), 744-8, 2003.
• Kondo, Richard P, Anderson, Robert H, Kupershmidt, Sabina, Roden, Dan M, Evans, Sylvia M Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol, 14(4), 383-91, 2003.
• Roden, Dan M Genetic polymorphisms, drugs, and proarrhythmia. J Interv Card Electrophysiol, 9(2), 131-5, 2003.
• Yang, Tao, Kanki, Hideaki, Roden, Dan M Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions. Circulation, 108(2), 132-4, 2003.
• Drolet, Benoit, Yang, Tao, Daleau, Pascal, Roden, Dan M, Turgeon, Jacques Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol, 41(6), 934-7, 2003.
• Kupershmidt, Sabina, Yang, Iris C-H, Hayashi, Kenshi, Wei, Jian, Chanthaphaychith, Siprachanh, Petersen, Christina I, Johns, Daivid C, George, Alfred L, Roden, Dan M, Balser, Jeffrey R The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J, 17(15), 2263-5, 2003.
• Arad, Michael, Moskowitz, Ivan P, Patel, Vickas V, Ahmad, Ferhaan, Perez-Atayde, Antonio R, Sawyer, Douglas B, Walter, Mark, Li, Guo H, Burgon, Patrick G, Maguire, Colin T, Stapleton, David, Schmitt, Joachim P, Guo, X X, Pizard, Anne, Kupershmidt, Sabina, Roden, Dan M, Berul, Charles I, Seidman, Christine E, Seidman, J G Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation, 107(22), 2850-6, 2003.
• Tan, Hanno L, Kupershmidt, Sabina, Zhang, Rong, Stepanovic, Svetlana, Roden, Dan M, Wilde, Arthur A M, Anderson, Mark E, Balser, Jeffrey R A calcium sensor in the sodium channel modulates cardiac excitability. Nature, 415(6870), 442-7, 2002.
• Yang, Ping, Kanki, Hideaki, Drolet, Benoit, Yang, Tao, Wei, Jian, Viswanathan, Prakash C, Hohnloser, Stefan H, Shimizu, Wataru, Schwartz, Peter J, Stanton, Marshall, Murray, Katherine T, Norris, Kris, George, Alfred L, Roden, Dan M Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation, 105(16), 1943-8, 2002.
• Gbadebo, T David, Trimble, Robert W, Khoo, Michelle S C, Temple, Joel, Roden, Dan M, Anderson, Mark E Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes. Circulation, 105(6), 770-4, 2002.
• Wu, Yuejin, Temple, Joel, Zhang, Rong, Dzhura, Igor, Zhang, Wei, Trimble, Robert, Roden, Dan M, Passier, Robert, Olson, Eric N, Colbran, Roger J, Anderson, Mark E Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation, 106(10), 1288-93, 2002.
• Roden, Dan M, Balser, Jeffrey R, George, Alfred L, Anderson, Mark E Cardiac ion channels. Annu Rev Physiol, 64431-75, 2002.
• Anderson, Mark E, Al-Khatib, Sana M, Roden, Dan M, Califf, Robert M, , Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J, 144(5), 769-81, 2002.
• Kupershmidt, Sabina, Yang, Iris C-H, Sutherland, Margaret, Wells, K Sam, Yang, Tao, Yang, Ping, Balser, Jeffrey R, Roden, Dan M Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous system. Cardiovasc Res, 56(1), 93-103, 2002.
• Kupershmidt, Sabina, Yang, Tao, Chanthaphaychith, Siprachanh, Wang, Zhiqing, Towbin, Jeffrey A, Roden, Dan M Defective human Ether-à-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus. J Biol Chem, 277(30), 27442-8, 2002.
• Kanki, Hideaki, Yang, Ping, Xie, Hong-Guang, Kim, Richard B, George, Alfred L, Roden, Dan M Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol, 13(3), 252-6, 2002.
• Roden, Dan M, George, Alfred L The genetic basis of variability in drug responses. Nat Rev Drug Discov, 1(1), 37-44, 2002.
• Roden, Dan M The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol, 40(2), 357-9, 2002.
• Roden, D M Defective ion channel function in the long QT syndrome: multiple unexpected mechanisms. J Mol Cell Cardiol, 33(2), 185-7, 2001.
• Wu, J, Roden, D M, Wikswo, J P Delayed activation and retrograde propagation in cardiac muscle: implication of virtual electrode effects. Ann Biomed Eng, 28(11), 1318-25, 2001.
• Yang, T, Snyders, D, Roden, D M Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol, 38(5), 737-44, 2001.
• Viswanathan, P C, Bezzina, C R, George, A L, Roden, D M, Wilde, A A, Balser, J R Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation, 104(10), 1200-5, 2001.
• Mazur, A, Anderson, M E, Bonney, S, Roden, D M Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol, 37(4), 1100-5, 2001.
• Roden, D M Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res, 50(2), 224-31, 2001.
• Anderson, M E, Mazur, A, Yang, T, Roden, D M Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther, 296(3), 806-10, 2001.
• Roden, D M, Brown, N J Preprescription genotyping: not yet ready for prime time, but getting there. Circulation, 103(12), 1608-10, 2001.
• Roden, D M Principles in pharmacogenetics. Epilepsia, 42 Suppl 544-8, 2001.
• Roden, DM QT bumps: unraveling the mechanisms. J Cardiovasc Electrophysiol, 12(12), 1379-80, 2001.
• Darbar, D, Fromm, M F, Dellorto, S, Roden, D M Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol, 12(1), 9-14, 2001.
• Tan HL, Kupershmidt S, Zhang R, Stepanovic S, Roden DM, Wilde AAM, Anderson ME, Balser JR "A Calcium Sensor in the Sodium Channel Modulates Cardiac Excitability." Nature, 415442-447, 2000.
• Sesti, F, Abbott, G W, Wei, J, Murray, K T, Saksena, S, Schwartz, P J, Priori, S G, Roden, D M, George, A L, Goldstein, S A A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A, 97(19), 10613-8, 2000.
• Roden, D M Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol, 11(8), 938-40, 2000.
• Roden, D M Antiarrhythmic drugs: from mechanisms to clinical practice. Heart, 84(3), 339-46, 2000.
• Camm, A J, Janse, M J, Roden, D M, Rosen, M R, Cinca, J, Cobbe, S M Congenital and acquired long QT syndrome. Eur Heart J, 21(15), 1232-7, 2000.
• Roden, D M Impact of recent molecular studies on evaluation of ventricular arrhythmias. J Interv Card Electrophysiol, 4 Suppl 17-16, 2000.
• Wei, J, Fish, F A, Myerburg, R J, Roden, D M, George, A L Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat, 15(4), 387-8, 2000.
• Wilde, A A, Roden, D M Predicting the long-QT genotype from clinical data: from sense to science. Circulation, 102(23), 2796-8, 2000.
• Chiang, C E, Roden, D M The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol, 36(1), 1-12, 2000.
• Roden, D M, Anderson, M E The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart, 84(3), 235-7, 2000.
• Roden, D M, Balser, J R A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. Cardiovasc Res, 44(2), 242-6, 1999.
• Nattel, S, Roden, D M, Escande, D A spotlight on electrophysiological remodeling and the molecular biology of ion channels. Cardiovasc Res, 42(2), 267-9, 1999.
• Roden, D M An overview of contemporary approaches to antiarrhythmic therapy. Jpn Circ J, 63(9), 655-8, 1999.
• Wu, Y, Roden, D M, Anderson, M E Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res, 84(8), 906-12, 1999.
• Wei, J, Wang, D W, Alings, M, Fish, F, Wathen, M, Roden, D M, George, A L Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation, 99(24), 3165-71, 1999.
• Roden, D M, Wilde, A A Drug-induced J point elevation: a marker for genetic risk of sudden death or ECG curiosity. J Cardiovasc Electrophysiol, 10(2), 219-23, 1999.
• Choy, A M, Darbar, D, Dell''Orto, S, Roden, D M Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol, 34(2), 396-401, 1999.
• Roden, D M, Kupershmidt, S From genes to channels: normal mechanisms. Cardiovasc Res, 42(2), 318-26, 1999.
• Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation, 99(5), 674-81, 1999.
• Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A M Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation, 99(4), 518-28, 1999.
• Priori, S G, Barhanin, J, Hauer, R N, Haverkamp, W, Jongsma, H J, Kleber, A G, McKenna, W J, Roden, D M, Rudy, Y, Schwartz, K, Schwartz, P J, Towbin, J A, Wilde, A Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J, 20(3), 174-95, 1999.
• Fromm, M F, Leake, B, Roden, D M, Wilkinson, G R, Kim, R B Human MRP3 transporter: identification of the 5''-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta, 1415(2), 369-74, 1999.
• Roden, D M, Spooner, P M Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol, 10(12), 1664-83, 1999.
• Fromm, M F, Kim, R B, Stein, C M, Wilkinson, G R, Roden, D M Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments. Circulation, 99(4), 552-7, 1999.
• Kim, R B, Wandel, C, Leake, B, Cvetkovic, M, Fromm, M F, Dempsey, P J, Roden, M M, Belas, F, Chaudhary, A K, Roden, D M, Wood, A J, Wilkinson, G R Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res, 16(3), 408-14, 1999.
• Roden, D M Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. Am J Cardiol, 84(9A), 29R-36R, 1999.
• Fromm, M F, Darbar, D, Dell''Orto, S, Roden, D M Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. J Pharmacol Exp Ther, 290(1), 253-8, 1999.
• Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA, Roden DM "Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system." Circulation Research, 84146-152, 1999.
• Kupershmidt, S, Yang, T, Anderson, M E, Wessels, A, Niswender, K D, Magnuson, M A, Roden, D M Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Circ Res, 84(2), 146-52, 1999.
• Mazur, A, Roden, D M, Anderson, M E Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation, 100(24), 2437-42, 1999.
• Kupershmidt S, Snyders DJ, Raes A, Roden DM "A K+ channel splice variant common in human heart lacks a C- terminal domain required for expression of rapidly-activating delayed rectifier current." J. Biol. Chem., 27327231-27235, 1998.
• Kupershmidt, S, Snyders, D J, Raes, A, Roden, D M A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current. J Biol Chem, 273(42), 27231-5, 1998.
• Choy, A M, Lang, C C, Roden, D M, Robertson, D, Wood, A J, Robertson, R M, Biaggioni, I Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J, 136(4 Pt 1), 664-71, 1998.
• Roden, D M Cardiovascular and Renal Advisory Panel of the FDA. Circulation, 97(12), 1107, 1998.
• Vitola, J, Vukanovic, J, Roden, D M Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol, 9(10), 1109-13, 1998.
• Thadani, U, Roden, D M FDA Panel report: January 1998. Circulation, 97(23), 2295-6, 1998.
• Roden, D M Mechanisms and management of proarrhythmia. Am J Cardiol, 82(4A), 49I-57I, 1998.
• Darbar, D, Fromm, M F, Dell''Orto, S, Kim, R B, Kroemer, H K, Eichelbaum, M, Roden, D M Modulation by dietary salt of verapamil disposition in humans. Circulation, 98(24), 2702-8, 1998.
• Kupershmidt S, Yang T, Roden DM "Modulation of cardiac sodium current phenotype by beta1-subunit expression." Circ , 83441-447, 1998.
• Kupershmidt, S, Yang, T, Roden, D M Modulation of cardiac Na+ current phenotype by beta1-subunit expression. Circ Res, 83(4), 441-7, 1998.
• Roden, D M Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol, 21(5), 1029-34, 1998.
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR "The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors." J Clin Invest, 101289-294, 1998.
• Kim, R B, Fromm, M F, Wandel, C, Leake, B, Wood, A J, Roden, D M, Wilkinson, G R The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 101(2), 289-94, 1998.
• Yang, T., Snyders, D.J., Roden, D.M "Rapid inactivation determines the rectification and [K+]o-dependence of the rapid component of the delayed rectifier K+ current in cardiac cells." Circ. Res., 80782-789, 1997.
• Roden, D M A practical approach to torsade de pointes. Clin Cardiol, 20(3), 285-90, 1997.
• Darbar, D, Dell''Orto, S, Mörike, K, Wilkinson, G R, Roden, D M Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther, 61(3), 292-300, 1997.
• Yang, T., Snyders, D.J., Roden, D.M "Inhibition of cardiac potassium currents by the vesnarinone analog OPC- 18790: Comparison with quinidine and dofetilide." J. Phannacol.Exp. Ther., 2801170-1175, 1997.
• Yang, T, Snyders, D J, Roden, D M Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther, 280(3), 1170-5, 1997.
• Choy, A M, Lang, C C, Chomsky, D M, Rayos, G H, Wilson, J R, Roden, D M Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 96(7), 2149-54, 1997.
• Yang, T, Snyders, D J, Roden, D M Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res, 80(6), 782-9, 1997.
• Kupershmidt ,S., Sutherland, M., King, D., Magnuson,M.A., Roden, D.M "Replacement by homologous recombination of the minK gene with lacZ reveals cell-specific minK expression." Biophys. J, 72A226, 1997.
• Roden, D M, George, A L Structure and function of cardiac sodium and potassium channels. Am J Physiol, 273(2 Pt 2), H511-25, 1997.
• Darbar, D., Smith, M., M?rike, K., Roden, D.M "Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pre-treatment with propranolol and diltiazem." Am. J. Cardiol, 771351-1355, 1996.
• Darbar, D, Smith, M, Mörike, K, Roden, D M Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Am J Cardiol, 77(15), 1351-5, 1996.
• Yang, T, Roden, D M Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation, 93(3), 407-11, 1996.
• Yang, T., Roden, D.M "Extracellular potassium modulation of drug block of IKr: Implications for Torsades de Pointes and reverse use-dependence." Circulation, 93407-411, 1996.
• Fritz, JD, Robertson, D Gene targeting approaches to the autonomic nervous system. J Auton Nerv Syst, 61(1), 1-5, 1996.
• Roden, D M Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. Circulation, 94(7), 1499-502, 1996.
• Roden, D.M "Ibutilide and treatment of atrial arrhythmias (Editorial)." Circulation, 941499-1502, 1996.
• Choy, A.M.J., Darbar, D., Dell'Orto, S., Roden, D.M "Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm." Circulation, 941202, 1996.
• Roden, D M Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. Am J Cardiol, 78(4A), 12-6, 1996.
• Roden, D M Is there a need for new antiarrhythmic drugs. Arch Mal Coeur Vaiss, 89 Spec No 113-8, 1996.
• Darbar, D, Dell''Orto, S, Wilkinson, G R, Roden, D M Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. Am J Health Syst Pharm, 53(6), 655-8, 1996.
• Roden, D.M., Lazzara, R., Rosen, M.R., Schwartz, P.J., Vincent, G.M., for the SADS Foundation Task Force on LQTS "Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions." Circulation, 941996-2012, 1996.
• Roden, D M, Lazzara, R, Rosen, M, Schwartz, P J, Towbin, J, Vincent, G M Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation, 94(8), 1996-2012, 1996.
• Yang, T., Roden, D.M "Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells)." Am. J. Physiol, 271H541-H547, 1996.
• Yang, T, Roden, D M Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). Am J Physiol, 271(2 Pt 2), H541-7, 1996.
• Rogers, RD, Bond, AH, Roden, DM Structural Chemistry of Poly(ethylene glycol) Complexes of Lead(II) Nitrate and Lead(II) Bromide. Inorg Chem, 35(24), 6964-6973, 1996.
• Kennedy, C J, Roden, D M, McAllister, I L Suprachoroidal effusion following argon laser trabeculoplasty. Aust N Z J Ophthalmol, 24(3), 279-82, 1996.
• Roden, D.M., George, A.L. Jr "The cardiac ion channels: Relevance to management of arrhythmias." Annu. Rev. Med, 47135-148, 1996.
• Roden, D M, George, A L The cardiac ion channels: relevance to management of arrhythmias. Annu Rev Med, 47135-48, 1996.
• Roden, D.M "Antiarrhythmic drugs." The Pharmacological Basis of Therapeutics, 9th Edition839-874, 1995.
• Echt, D.S., Lee, J.T., Murray, K.T., Vorperian, V., Borganelli, S.M., Crawford, D.M., Friedrich, T., Roden, D.M "A randomized, double-blind, placebo-controlled dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias." J. Cardiovasc. Electrophys, 6687-699, 1995.
• Echt, D S, Lee, J T, Murray, K T, Vorperian, V, Borganelli, S M, Crawford, D M, Friedrich, T, Roden, D M A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol, 6(9), 687-99, 1995.
• Wei, J., Wathen, M., Murray, K., Daw, R., Roden, D., George, A.L. Jr "Absence of HERG and SCN5A mutations in acquired long QT syndrome." Circulation, 921-275, 1995.
• Yang, T, Kupershmidt, S, Roden, D M Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. Circ Res, 77(6), 1246-53, 1995.
• Yang, T., Kupershmidt, S., Roden, D.M "Anti-minK antisense decreases the amplitude of the rapidly-activating cardiac delayed rectifier K+ current." Circ. Res, 771246-1253, 1995.
• Yang, T., Snyders, D.J., Roden, D.M "Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed rectifier K+ current (IKr) in AT- I cells: Concentration-, time-, voltage- and use-dependent effects." Circulation, 911799-1806, 1995.
• Yang, T, Snyders, D J, Roden, D M Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation, 91(6), 1799-806, 1995.
• Yang, T., Prakash, C., Roden, D.M., Snyders, D.J "Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers." J. Pharmacol, 15267-274, 1995.
• Yang, T, Prakash, C, Roden, D M, Snyders, D J Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol, 115(2), 267-74, 1995.
• Roden, D.M., George, A.L. Jr, Bennett, P.B "Recent advances in understanding the molecular mechanisms of the long QT syndrome. Invited review." J. Cardiovasc. Electrophysiol, 61023-1031, 1995.
• Roden, D M, George, A L, Bennett, P B Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol, 6(11), 1023-31, 1995.
• Turgeon, J., Daleau, P., Bennett, P.B., Wiggins, S.S., Selby, L., Roden, D.M "Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes." Circ. Res, 75879-886, 1994.
• Turgeon, J, Daleau, P, Bennett, P B, Wiggins, S S, Selby, L, Roden, D M Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res, 75(5), 879-86, 1994.
• Vorperian, V R, Wisialowski, T A, Deegan, R, Roden, D M Effect of hypercapnic acidemia on anisotropic propagation in the canine ventricle. Circulation, 90(1), 456-61, 1994.
• Echt, D S, Gremillion, S T, Lee, J T, Roden, D M, Murray, K T, Borganelli, M, Crawford, D M, Stewart, J R, Hammon, J W Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol, 5(9), 752-60, 1994.
• Yang, T., Wathen, M.S., Felipe, A., Tamkun, M.M., Snyders, D.J., Roden, D.M "K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells)." Circ. Res, 75870-878, 1994.
• Yang, T, Wathen, M S, Felipe, A, Tamkun, M M, Snyders, D J, Roden, D M K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res, 75(5), 870-8, 1994.
• Roden, D M Mirror, mirror on the wall ... stereochemistry in therapeutics. Circulation, 89(5), 2451-3, 1994.
• Roden, D.M "Mirror, mirror on the wall: Stereochemistry in therapeutics (Editorial)." Circulation, 892451-2453, 1994.
• Roden, D M, Levy, F E Oncocytoma of the parotid gland presenting with nerve paralysis. Otolaryngol Head Neck Surg, 110(6), 587-90, 1994.
• Roden, D.M., Murray, K.T "Pharmacokinetics, phannacodynamics and pharmacogenetics." Zipes, D.P., Jalife, J. (eds): Cardiac Electrophysiology: From Cell to Bedside, 2nd edition, W.B. Saunders, 1287-1296, 1994.
• Mörike, K E, Roden, D M Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther, 55(1), 28-34, 1994.
• Roden, D M Risks and benefits of antiarrhythmic therapy. N Engl J Med, 331(12), 785-91, 1994.
• Roden, D.M "Risks and benefits of antiarrhythmic therapy. Invited review." N. Engl. J. Med., , 331785-791, 1994.
• Roden, D.M., Tamkun, M.M "Toward a molecular view of cardiac arrhythmogenesis." Trends Cardiovasc. Med. , 4278-285, 1994.
• Roden, D M Current status of class III antiarrhythmic drug therapy. Am J Cardiol, 72(6), 44B-49B, 1993.
• Roden, D M Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J, 14 Suppl H56-61, 1993.
• Davies, R F, Siddoway, L A, Shaw, L, Barbey, J T, Roden, D M, Woosley, R L Immediate- versus controlled-release disopyramide: importance of saturable binding. Clin Pharmacol Ther, 54(1), 16-22, 1993.
• Roden, D M, Pomerantz, R A Penetrating injuries to the neck: a safe, selective approach to management. Am Surg, 59(11), 750-3, 1993.
• Roden, D M Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol, 72(16), 45F-50F, 1993.
• Roden, D M Torsade de pointes. Clin Cardiol, 16(9), 683-6, 1993.
• Roden, D M Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol, 72(4), 51A-55A, 1993.
• Wong, W, Pavlou, H N, Birgersdotter, U M, Hilleman, D E, Mohiuddin, S M, Roden, D M Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol, 69(3), 206-12, 1992.
• Birgersdotter, U M, Wong, W, Turgeon, J, Roden, D M Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol, 33(3), 275-80, 1992.
• Turgeon, J, Wisialowski, T A, Wong, W, Altemeier, W A, Wikswo, J P, Roden, D M Suppression of longitudinal versus transverse conduction by sodium channel block. Effects of sodium bolus. Circulation, 85(6), 2221-6, 1992.
• Greene, H L, Roden, D M, Katz, R J, Woosley, R L, Salerno, D M, Henthorn, R W The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol, 19(5), 894-8, 1992.
• Turgeon, J, Funck-Brentano, C, Gray, H T, Pavlou, H N, Prakash, C, Blair, I A, Roden, D M Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther, 49(5), 488-96, 1991.
• Ware, D L, Lee, J T, Murray, K T, Hanyok, J J, Roden, D M, Echt, D S Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study. Pacing Clin Electrophysiol, 14(9), 1343-50, 1991.
• Tamkun, M M, Knoth, K M, Walbridge, J A, Kroemer, H, Roden, D M, Glover, D M Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J, 5(3), 331-7, 1991.
• Turgeon, J, Evans, W E, Relling, M V, Wilkinson, G R, Roden, D M Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol, 32(3), 283-8, 1991.
• Pavlou, H N, Funck-Brentano, C, Lineberry, M D, Woosley, R L, Roden, D M Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. Clin Pharmacol Ther, 49(3), 314-21, 1991.
• Balser, J R, Roden, D M, Bennett, P B Single inward rectifier potassium channels in guinea pig ventricular myocytes. Effects of quinidine. Biophys J, 59(1), 150-61, 1991.
• Balser, J.R., Bennett, P.B., Hondeghem, L.M., Roden, D.M "Suppression of time-dependent outward current in guinea pig ventricular myocytes: Actions of quinidine and amiodarone." Circ. Res., 69519-529, 1991.
• Balser, J R, Bennett, P B, Hondeghem, L M, Roden, D M Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res, 69(2), 519-29, 1991.
• Wikswo, J P, Wisialowski, T A, Altemeier, W A, Balser, J R, Kopelman, H A, Roden, D M Virtual cathode effects during stimulation of cardiac muscle. Two-dimensional in vivo experiments. Circ Res, 68(2), 513-30, 1991.
• Funck-Brentano, C, Silberstein, D J, Roden, D M, Wood, A J, Woosley, R L A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. Br J Clin Pharmacol, 30(2), 195-202, 1990.
• Turgeon, J, Pavlou, H N, Wong, W, Funck-Brentano, C, Roden, D M Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther, 255(2), 642-9, 1990.
• Balser, J R, Roden, D M, Bennett, P B Global parameter optimization for cardiac potassium channel gating models. Biophys J, 57(3), 433-44, 1990.
• Campbell, R M, Woosley, R L, Iansmith, D H, Roden, D M Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. Pacing Clin Electrophysiol, 13(1), 30-6, 1990.
• Funck-Brentano, C, Kroemer, H K, Lee, J T, Roden, D M Propafenone. N Engl J Med, 322(8), 518-25, 1990.
• Zhou, H H, Anthony, L B, Roden, D M, Wood, A J Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther, 47(6), 686-93, 1990.
• Turgeon, J, Kroemer, H K, Prakash, C, Blair, I A, Roden, D M Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci, 79(2), 91-5, 1990.
• Fish, F A, Prakash, C, Roden, D M Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation, 82(4), 1362-9, 1990.
• Murray, K T, Reilly, C, Koshakji, R P, Roden, D M, Lineberry, M D, Wood, A J, Siddoway, L A, Barbey, J T, Woosley, R L Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest, 85(3), 836-42, 1990.
• Lee, J T, Kroemer, H K, Silberstein, D J, Funck-Brentano, C, Lineberry, M D, Wood, A J, Roden, D M, Woosley, R L The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med, 322(25), 1764-8, 1990.
• Balser, J.R., Bennett, P.B., Roden, D.M "Time-dependent outward current in guinea pig myocytes: Gating kinetics of the delayed rectifier." J. Gen. Physiol, 96835-863, 1990.
• Balser, J R, Bennett, P B, Roden, D M Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier. J Gen Physiol, 96(4), 835-63, 1990.
• Fish, F A, Roden, D M A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs. Med Toxicol Adverse Drug Exp, 4(6), 400-11, 1989.
• Bajaj, A K, Woosley, R L, Roden, D M Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation, 80(4), 994-1002, 1989.
• Roden, D M, Lee, J T, Woosley, R L, Echt, D S Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Circulation, 80(5), 1247-58, 1989.
• Greene, H L, Richardson, D W, Barker, A H, Roden, D M, Capone, R J, Echt, D S, Friedman, L M, Gillespie, M J, Hallstrom, A P, Verter, J Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(1), 1-6, 1989.
• Greene, H L, Richardson, D W, Hallstrom, A P, McBride, R, Capone, R J, Barker, A H, Roden, D M, Echt, D S Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol, 63(7), 393-8, 1989.
• Funck-Brentano, C, Turgeon, J, Woosley, R L, Roden, D M Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther, 249(1), 134-42, 1989.
• Kroemer, H K, Turgeon, J, Parker, R A, Roden, D M Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther, 46(5), 584-90, 1989.
• Funck-Brentano, C, Kroemer, H K, Pavlou, H, Woosley, R L, Roden, D M Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol, 27(4), 435-44, 1989.
• Turgeon, J, Funck-Brentano, C, Gray, H T, Roden, D M Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. J Chromatogr, 490(1), 165-74, 1989.
• Roden, D M Magnesium treatment of ventricular arrhythmias. Am J Cardiol, 63(14), 43G-46G, 1989.
• Murray, K T, Barbey, J T, Kopelman, H A, Siddoway, L A, Echt, D S, Woosley, R L, Roden, D M Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. Clin Pharmacol Ther, 45(5), 553-61, 1989.
• Funck-Brentano, C, Light, R T, Lineberry, M D, Wright, G M, Roden, D M, Woosley, R L Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. J Cardiovasc Pharmacol, 14(3), 364-73, 1989.
• Turgeon, J, Roden, D M Pharmacokinetic profile of encainide. Clin Pharmacol Ther, 45(6), 692-4, 1989.
• The CAST Investigators "Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction." 321, N. Eng. J. Med406-412, 1989.
• Davies, R F, Lineberry, M D, Funck-Brentano, C, Echt, D S, Lee, J T, Capuzzi, D M, Roden, D M, Woosley, R L Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Clin Pharmacol Ther, 46(3), 324-34, 1989.
• Kroemer, H K, Funck-Brentano, C, Silberstein, D J, Wood, A J, Eichelbaum, M, Woosley, R L, Roden, D M Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation, 79(5), 1068-76, 1989.
• Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Circulation, 77(2), 380-91, 1988.
• Roden, D M, Woosley, R L Clinical pharmacokinetics of encainide. Clin Pharmacokinet, 14(3), 141-7, 1988.
• Woosley, R L, Wood, A J, Roden, D M Drug therapy. Encainide. N Engl J Med, 318(17), 1107-15, 1988.
• Roden, D M, Nadeau, J H, Primm, R K Electrophysiologic and hemodynamic effects of chronic oral therapy with the alpha 2-agonists clonidine and tiamenidine in hypertensive volunteers. Clin Pharmacol Ther, 43(6), 648-54, 1988.
• Kopelman, H A, Woosley, R L, Lee, J T, Roden, D M, Echt, D S Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol, 61(13), 1006-11, 1988.
• Thompson, K A, Murray, J J, Blair, I A, Woosley, R L, Roden, D M Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther, 43(6), 636-42, 1988.
• Thompson, K A, Iansmith, D H, Siddoway, L A, Woosley, R L, Roden, D M Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther, 244(3), 950-5, 1988.
• Roden, D M, Bennett, P B, Snyders, D J, Balser, J R, Hondeghem, L M Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res, 62(5), 1055-8, 1988.
• Roden, D M Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. Am J Cardiol, 62(12), 34H-38H, 1988.
• Wang, T, Siddoway, L A, Thompson, K A, Conard, G J, Bergstrand, R H, Kvam, D, Roden, D M, Woosley, R L The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. Clin Pharmacol Ther, 43(5), 499-508, 1988.
• Barbey, J T, Thompson, K A, Echt, D S, Woosley, R L, Roden, D M Tocainide plus quinidine for treatment of ventricular arrhythmias. Am J Cardiol, 61(8), 570-3, 1988.
• Thompson, K A, Blair, I A, Woosley, R L, Roden, D M Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. J Pharmacol Exp Ther, 241(1), 84-90, 1987.
• Roden, D M, Iansmith, D H Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med, 82(3A), 18-23, 1987.
• Bajaj, A K, Kopelman, H A, Wikswo, J P, Cassidy, F, Woosley, R L, Roden, D M Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. Circulation, 75(5), 1065-73, 1987.
• Roden, D M, Iansmith, D H, Woosley, R L Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. J Pharmacol Exp Ther, 243(3), 1218-24, 1987.
• Woosley, R L, Roden, D M Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol, 59(11), 19E-25E, 1987.
• Siddoway, L A, Barbey, J T, Roden, D M, Woosley, R L Pharmacologic evaluation of standard and controlled-release disopyramide. Angiology, 38(2 Pt 2), 184-7, 1987.
• Siddoway, L A, Thompson, K A, McAllister, C B, Wang, T, Wilkinson, G R, Roden, D M, Woosley, R L Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation, 75(4), 785-91, 1987.
• Roden, D M, Thompson, K A, Hoffman, B F, Woosley, R L Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol, 8(1 Suppl A), 73A-78A, 1986.
• Woosley, R L, Roden, D M, Dai, G H, Wang, T, Altenbern, D, Oates, J, Wilkinson, G R Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther, 39(3), 282-7, 1986.
• Wang, T, Bergstrand, R H, Thompson, K A, Siddoway, L A, Duff, H J, Woosley, R L, Roden, D M Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol, 57(13), 1160-5, 1986.
• Roden, D M, Wood, A J, Wilkinson, G R, Woosley, R L Disposition kinetics of encainide and metabolites. Am J Cardiol, 58(5), 4C-9C, 1986.
• Roden, D M, Woosley, R L Drug therapy. Flecainide. N Engl J Med, 315(1), 36-41, 1986.
• Roden, D M, Woosley, R L Drug therapy. Tocainide. N Engl J Med, 315(1), 41-5, 1986.
• Kolodgie, F D, Dawson, A K, Roden, D M, Forman, M B, Virmani, R Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Am Heart J, 112(6), 1192-201, 1986.
• Woosley, R L, Echt, D S, Roden, D M Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Am J Cardiol, 57(3), 25B-33B, 1986.
• Duff, H J, Kolodgie, F D, Roden, D M, Woosley, R L Electropharmacologic synergism with mexiletine and quinidine. J Cardiovasc Pharmacol, 8(4), 840-6, 1986.
• Bergstrand, R H, Wang, T, Roden, D M, Avant, G R, Sutton, W W, Siddoway, L A, Wolfenden, H, Woosley, R L, Wilkinson, G R, Wood, A J Encainide disposition in patients with chronic cirrhosis. Clin Pharmacol Ther, 40(2), 148-54, 1986.
• Bergstrand, R H, Wang, T, Roden, D M, Stone, W J, Wolfenden, H T, Woosley, R L, Wilkinson, G R, Wood, A J Encainide disposition in patients with renal failure. Clin Pharmacol Ther, 40(1), 64-70, 1986.
• Roden, D M, Woosley, R L, Primm, R K Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J, 111(6), 1088-93, 1986.
• Hammon, J W, Echt, D S, Merrill, W H, Primm, K R, Woosley, R L, Smith, R F, Roden, D M, Bender, H W Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. Ann Surg, 203(6), 679-84, 1986.
• Roden, D M Pharmacologic information required for design of programmed electrical stimulation protocols. Circulation, 73(2 Pt 2), II39-44, 1986.
• Roden, D M, Hoffman, B F Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res, 56(6), 857-67, 1985.
• Roden, D.M., Hoffman, B "Action potential prolongation and induction of abnormnal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length." Circ. Res, 56857-867, 1985.
• Roden, D M Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents. Postgrad Med, 78(4), 28-37, 1985.
• Duff, H J, Roden, D M, Yacobi, A, Robertson, D, Wang, T, Maffucci, R J, Oates, J A, Woosley, R L Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. Am J Cardiol, 55(4), 395-401, 1985.
• Siddoway, L A, Roden, D M, Woosley, R L Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovasc Clin, 15(3), 199-248, 1985.
• Roden, D M, Woosley, R L QT prolongation and arrhythmia suppression. Am Heart J, 109(2), 411-5, 1985.
• Duff, H J, Roden, D M, Carey, E L, Wang, T, Primm, R K, Woosley, R L Spectrum of antiarrhythmic response to encainide. Am J Cardiol, 56(13), 887-91, 1985.
• Roden, D M Tocainide and mexiletine. Orally effective lidocaine analogues. Arch Intern Med, 145(3), 417-8, 1985.
• Woosley, R L, Echt, D S, Roden, D M Treatment of ventricular arrhythmias in the failing heart: pharmacologic and clinical considerations. Ration Drug Ther, 19(10), 1-7, 1985.
• Riddell, J G, McAllister, C B, Wilkinson, G R, Wood, A J, Roden, D M A new method for constant plasma drug concentrations: application to lidocaine. Ann Intern Med, 100(1), 25-8, 1984.
• Woosley, R L, Cerskus, I, Roden, D M Antiarrhythmic therapy: clinical pharmacology update. J Clin Pharmacol, 24(7), 295-305, 1984.
• Siddoway, L A, Roden, D M, Woosley, R L Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol, 54(9), 9D-12D, 1984.
• Dawson, A K, Roden, D M, Duff, H J, Woosley, R L, Smith, R F Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. Am J Cardiol, 54(6), 654-8, 1984.
• Roden, D M, Dawson, A K, Duff, H J, Woosley, R L, Smith, R F Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. J Cardiovasc Pharmacol, 6(4), 588-95, 1984.
• Carey, E L, Duff, H J, Roden, D M, Primm, R K, Wilkinson, G R, Wang, T, Oates, J A, Woosley, R L Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest, 73(2), 539-47, 1984.
• Woosley, R L, Siddoway, L A, Duff, H J, Roden, D M Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol, 53(5), 59B-65B, 1984.
• Wang, T, Roden, D M, Wolfenden, H T, Woosley, R L, Wood, A J, Wilkinson, G R Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther, 228(3), 605-11, 1984.
• Duff, H J, Roden, D M, Marney, S, Colley, D G, Maffucci, R, Primm, R K, Oates, J A, Woosley, R L Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. Am Heart J, 107(3), 585-9, 1984.
• Woosley, R L, Siddoway, L A, Thompson, K, Cerskus, I, Roden, D M Potential applications of free drug level monitoring in cardiovascular therapy. Clin Pharmacokinet, 9 Suppl 179-83, 1984.
• Duff, H J, Oates, J A, Roden, D M, Woosley, R L The antiarrhythmic activity of meobentine sulfate in man. J Cardiovasc Pharmacol, 6(4), 650-6, 1984.
• Siddoway, L A, McAllister, C B, Wilkinson, G R, Roden, D M, Woosley, R L Amiodarone dosing: a proposal based on its pharmacokinetics. Am Heart J, 106(4 Pt 2), 951-6, 1983.
• Roden, D M, Woosley, R L Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. Pharmacol Ther, 23(2), 179-91, 1983.
• Duff, H J, Dawson, A K, Roden, D M, Oates, J A, Smith, R F, Woosley, R L Electrophysiologic actions of O-demethyl encainide: an active metabolite. Circulation, 68(2), 385-91, 1983.
• Duff, H J, Roden, D M, Brorson, L, Wood, A J, Dawson, A K, Primm, R K, Oates, J A, Smith, R F, Woosley, R L Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol, 2(6), 1134-40, 1983.
• Woosley, R L, Roden, D M Importance of metabolites in antiarrhythmic therapy. Am J Cardiol, 52(6), 3C-7C, 1983.
• Roden, D M, Duff, H J, Altenbern, D, Woosley, R L Antiarrhythmic activity of the O-demethyl metabolite of encainide. J Pharmacol Exp Ther, 221(3), 552-7, 1982.
• Duff, H J, Roden, D M, Dawson, A K, Oates, J A, Smith, R F, Woosley, R L Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. Am J Cardiol, 50(2), 305-12, 1982.
• Woosley, R L, Reele, S B, Roden, D M, Nies, A S, Oates, J A Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. Clin Pharmacol Ther, 32(3), 313-21, 1982.
• Woosley, R L, Roden, D M, Duff, H J, Oates, J A Selection of an antiarrhythmic drug for a sudden-death-prevention trial. Am Heart J, 103(4 Pt 2), 737-45, 1982.
• Roden, D M, Duff, H J, Primm, R K, Kronenberg, M W, Woosley, R L Control of ventricular preexcitation and associated arrhythmias by encainide. Am Heart J, 102(4), 794-7, 1981.
• Roden, D M, Duff, H J, Reele, S B, Woosley, R L, Oates, J A, Smith, R F, Friesinger, G C Recurrent ventricular tachycardia in the absence of overt heart disease: clinical characteristics and response to drug therapy. South Med J, 74(9), 1090-4, 1981.
• Duff, H J, Roden, D M, Maffucci, R J, Vesper, B S, Conard, G J, Higgins, S B, Oates, J A, Smith, R F, Woosley, R L Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol, 48(6), 1133-40, 1981.
• Roden, D M, Reele, S B, Higgins, S B, Wilkinson, G R, Smith, R F, Oates, J A, Woosley, R L Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol, 46(3), 463-8, 1980.
• Roden, D M, Roden, D M, Reele, S B, Reele, S B, Higgins, S B, Higgins, S B, Carr, R K, Carr, R K, Smith, R F, Smith, R F, Oates, J A, Oates, J A, Woosley, R L, Woosley, R L Tocainide therapy for refractory ventricular arrhythmias. Am Heart J, 100(1), 15-22, 1980.
• Roden, D M, Reele, S B, Higgins, S B, Mayol, R F, Gammans, R E, Oates, J A, Woosley, R L Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. N Engl J Med, 302(16), 877-82, 1980.

Education

• M.D. - McGill University, 1974
• Fellowship - Vanderbilt University Medical Center, 1981
• Fellowship - Vanderbilt University Medical Center, 1981
• Residency - Royal Victoria Hospital, 1978
• Internship - Royal Victoria Hospital, 1975
• Post Graduate Training - McGill University Hospital